Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell NHL > 60 Years or With Compromised Cardiac Status

NCT00333008 is registered in ClinicalTrials.gov with The Alvin and Lois Lapidus Cancer Institute as lead sponsor.

NCT NCT00333008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00333008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell NHL > 60 Years or With Compromised Cardiac Status
Lead sponsor
The Alvin and Lois Lapidus Cancer Institute
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2006
Completion date
Not reported
Enrollment
27
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, lymphoma, non-hodgkin